INT170208

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.49
First Reported 2001
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 15
Total Number 18
Disease Relevance 6.07
Pain Relevance 0.45

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Lpl) extracellular region (Lpl) plasma membrane (Lpl)
lipid metabolic process (Lpl)
Anatomy Link Frequency
liver 2
F19 2
macrophages 1
tubes 1
juvenile 1
Lpl (Mus musculus)
Pain Link Frequency Relevance Heat
agonist 46 95.76 Very High Very High Very High
cytokine 55 90.64 High High
Bile 7 84.08 Quite High
alcohol 3 73.08 Quite High
Inflammation 56 66.32 Quite High
Inflammatory response 17 16.24 Low Low
imagery 52 5.00 Very Low Very Low Very Low
isoflurane 16 5.00 Very Low Very Low Very Low
anesthesia 13 5.00 Very Low Very Low Very Low
cINOD 8 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Repression 13 100.00 Very High Very High Very High
Disorder Of Lipid Metabolism 129 98.84 Very High Very High Very High
Disease 31 98.84 Very High Very High Very High
Obesity 216 97.32 Very High Very High Very High
Sprains And Strains 30 95.60 Very High Very High Very High
Atherosclerosis 104 95.40 Very High Very High Very High
Retinoblastoma 2 94.56 High High
Systemic Lupus Erythematosus 1 94.44 High High
Hyperlipidemia 21 92.28 High High
Dyslipidemia /

Combined Dyslipidemia

9 90.36 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In such a way, Kit loss-of-function mimicked the downregulation of Lpin1, Lpl and Vldlr leading to juvenile steatosis and growth retardation.
Negative_regulation (downregulation) of Lpl in juvenile
1) Confidence 0.49 Published 2007 Journal BMC Dev Biol Section Body Doc Link PMC1940254 Disease Relevance 0.37 Pain Relevance 0
In addition to the Lpin1 downregulation, repression of Lpl and Vldlr would also contribute to the hepatic Kit-induced phenotype.
Negative_regulation (repression) of Lpl associated with repression
2) Confidence 0.49 Published 2007 Journal BMC Dev Biol Section Body Doc Link PMC1940254 Disease Relevance 0.39 Pain Relevance 0
Expression profiling for key genes participating to the metabolism, the transport, the modification, lipidogenesis and biliary acid synthesis in the liver revealed that only a few genes, namely Vldlr, Lpin1 and Lpl were downregulated in Kit mutants.
Negative_regulation (downregulated) of Lpl in liver
3) Confidence 0.49 Published 2007 Journal BMC Dev Biol Section Body Doc Link PMC1940254 Disease Relevance 0.09 Pain Relevance 0
Expression of most of the genes remained unchanged in wild-type and mutant individuals at 10.5 dpp (not shown) except for the very low density lipoprotein receptor (Vldlr), the Lpin1 and the lipoprotein lipase (Lpl) genes that were downregulated in Sco5/Sco5 mutants compared to wild-type littermates (Figure 6).
Negative_regulation (downregulated) of Lpl
4) Confidence 0.36 Published 2007 Journal BMC Dev Biol Section Body Doc Link PMC1940254 Disease Relevance 0.09 Pain Relevance 0.04
We found that, in addition to the classical phenotypes, mutations of Kit induced juvenile steatosis, associated with the downregulation of the three genes, VldlR, Lpin1 and Lpl, controlling lipid metabolism in the post-natal liver.
Negative_regulation (downregulation) of Lpl in liver
5) Confidence 0.36 Published 2007 Journal BMC Dev Biol Section Abstract Doc Link PMC1940254 Disease Relevance 0.07 Pain Relevance 0
Expression of most of the genes remained unchanged in wild-type and mutant individuals at 10.5 dpp (not shown) except for the very low density lipoprotein receptor (Vldlr), the Lpin1 and the lipoprotein lipase (Lpl) genes that were downregulated in Sco5/Sco5 mutants compared to wild-type littermates (Figure 6).
Negative_regulation (downregulated) of lipoprotein lipase
6) Confidence 0.36 Published 2007 Journal BMC Dev Biol Section Body Doc Link PMC1940254 Disease Relevance 0.09 Pain Relevance 0.04
-mediated decrease in LPL promoter activity could be prevented by expression of DN PKB.
Negative_regulation (decrease) of LPL promoter
7) Confidence 0.34 Published 2008 Journal Cell Signal Section Body Doc Link PMC2586094 Disease Relevance 0 Pain Relevance 0.05
-mediated suppression of LPL promoter activity observed when the cells were transfected with the control pSG5 vector only was abrogated in cells expressing DN CK2 (Fig. 1).
Negative_regulation (suppression) of LPL promoter
8) Confidence 0.25 Published 2008 Journal Cell Signal Section Body Doc Link PMC2586094 Disease Relevance 0 Pain Relevance 0
-mediated inhibition of LPL enzymatic activity and mRNA expression in J774.2 macrophages [14].
Negative_regulation (inhibition) of LPL in macrophages
9) Confidence 0.25 Published 2008 Journal Cell Signal Section Body Doc Link PMC2586094 Disease Relevance 0 Pain Relevance 0
ANGPTL4 is a circulating lipoprotein lipase (LPL) inhibitor and plays a key role in regulating deposition of triglycerides in adipocytes [2], [3].
Negative_regulation (inhibitor) of LPL in adipocytes associated with obesity
10) Confidence 0.17 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2948012 Disease Relevance 0.92 Pain Relevance 0.04
In addition, the signature increase in triglycerides was also seen, an observation compatible with an LPL inhibition caused by the increase in ANGPTL4 serum levels.
Negative_regulation (inhibition) of LPL
11) Confidence 0.15 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2948012 Disease Relevance 0.07 Pain Relevance 0
Interestingly and in consonance with this, an increase in triglycerides in the VLDL fraction was seen, as possible consequence of LPL inhibition, whereas the mono-colonization with F19 had no effect on cholesterol content in any of the lipoprotein fractions (Figure 5B).


Spec (possible) Negative_regulation (inhibition) of LPL in F19
12) Confidence 0.13 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2948012 Disease Relevance 0.28 Pain Relevance 0
At present, the Lactobacillus F19 seems to be a better inducer of the LPL inhibitor than the Bifidobacterium BB12.
Negative_regulation (inhibitor) of LPL in F19
13) Confidence 0.13 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2948012 Disease Relevance 0.39 Pain Relevance 0
Hepatic lipase (HL) activity was determined in tubes where the lipoprotein lipase (LPL) was inhibited by 2 M NaCl.
Negative_regulation (inhibited) of LPL in tubes
14) Confidence 0.08 Published 2001 Journal BMC Biochem Section Body Doc Link PMC31329 Disease Relevance 0.22 Pain Relevance 0
The activity of ApoC-III, which is an inhibitor of both LPL activity and remnant clearance, is lowered by PPAR?
Negative_regulation (inhibitor) of LPL
15) Confidence 0.08 Published 2010 Journal Nuclear Receptor Signaling Section Body Doc Link PMC2858266 Disease Relevance 0.81 Pain Relevance 0.16
LPL activity is significantly decreased with the progression of the disease due
Negative_regulation (decreased) of LPL associated with disease
16) Confidence 0.07 Published 2008 Journal Clinical and Developmental Immunology Section Body Doc Link PMC2423423 Disease Relevance 0.83 Pain Relevance 0
natural LPL inhibitor, and stimulates the uptake of cellular fatty acids and
Negative_regulation (inhibitor) of LPL
17) Confidence 0.07 Published 2008 Journal PPAR Research Section Body Doc Link PMC2435221 Disease Relevance 0.92 Pain Relevance 0.03
at the LPL gene promoter is attenuated upon complex formation of ligand-bound PPAR?
Negative_regulation (attenuated) of LPL
18) Confidence 0.06 Published 2009 Journal PPAR Research Section Body Doc Link PMC2830574 Disease Relevance 0.38 Pain Relevance 0.09

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox